Diligence memo · auto-generated · as of July 2, 2026
Kato Pharmaceuticals, Inc.
Kato Pharmaceuticals, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Kato Pharmaceuticals, Inc. operates in Pharmaceuticals, based in LAGUNA HILLS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Kato Pharmaceuticals, Inc. has raised $8.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.0M on 2018-10-11.
Most recent recorded round closed around 2018-10-11.
Valuation (modeled)modeled
Provath models Kato Pharmaceuticals, Inc. at approximately $248M (range $9.2M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.39× the median modeled value of Series A Pharmaceuticals companies in 2016–2018 (88 peers) — value vs value, same stage and era. Within the normal band (139% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 7.7 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 50% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 72% of those peers.
Closest niche peers: Arbutus Biopharma Corp, Rvc 360, Llc, Sterrx, Llc, Ribometrix, Inc., Neuraltus Pharmaceuticals, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.